Skip to main content

Advertisement

SpringerLink
Log in

Platinum-refractory germ cell tumors: an update on current treatment options and developments

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

In general, 50 % up to 80 % of metastasized germ cell tumor patients can be cured by platinum-based chemotherapy. However, 3–5 % of patients will still die of platinum-refractory disease and new systemic treatment options are needed to improve treatment success in this difficult setting. This review aims to give an overview on treatment options and current developments in the field of platinum-refractory male germ cell tumors.

Methods

A comprehensive literature search was conducted searching PubMed, Medline, Cochrane and Embase to identify clinical trials regarding the treatment of platinum-refractory disease. ASCO, EAU and ESMO conference proceedings were searched to identify unpublished results of relevant trials. Comprehensive review papers were hand searched for additional references. Clinicaltrials.gov was checked for ongoing clinical trials in the field of platinum-refractory germ cell tumors.

Results

Outcome of platinum-refractory disease remains poor. Single-agents with reasonable activity are gemcitabine, oxaliplatin and paclitaxel, but complete remissions resulting in long-term survival could not be achieved. The triple-combination of gemcitabine, oxaliplatin and paclitaxel followed by resection of residual masses provides the best outcomes with objective responses in 51 % of patients and long-term survival in approximately 10–15 %. To date, no molecularly targeted agent has shown reasonable activity.

Conclusions

Treatment options for platinum-refractory disease are limited, but a small subset of patients may achieve long-term disease-free survival by multimodal treatment. The potential of novel targeted agents, i.e. by immune-checkpoint-inhibition remains to be defined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huyghe E, Plante P, Thonneau PF (2007) Testicular cancer variations in time and space in Europe. Eur Urol 51(3):621–628

    Article  PubMed  Google Scholar 

  2. IGCCCG (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15(2):594–603

    Article  Google Scholar 

  3. van Dijk MR, Steyerberg EW, Habbema JD (2006) Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur J Cancer 42(7):820–826

    Article  PubMed  Google Scholar 

  4. Horwich A, Shipley J, Huddart R (2006) Testicular germ-cell cancer. Lancet 367(9512):754–765

    Article  CAS  PubMed  Google Scholar 

  5. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14(10):2638–2645

    Article  CAS  PubMed  Google Scholar 

  6. Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Flechon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK, International Prognostic Factors Study G (2010) Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28(33):4906–4911

    Article  PubMed  Google Scholar 

  7. Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8(11):1777–1781

    Article  CAS  PubMed  Google Scholar 

  8. Gandaglia G, Becker A, Trinh QD, Abdollah F, Schiffmann J, Roghmann F, Tian Z, Montorsi F, Briganti A, Karakiewicz PI, Sun M (2014) Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis. Eur J Surg Oncol 40(1):103–112

    Article  CAS  PubMed  Google Scholar 

  9. O’Carrigan B, Grimison P (2015) Current chemotherapeutic approaches for recurrent or refractory germ cell tumors. Urol Oncol 33(8):343–354

    Article  PubMed  Google Scholar 

  10. Oechsle K, Kollmannsberger C, Honecker F, Mayer F, Waller CF, Hartmann JT, Boehlke I, Bokemeyer C, German Testicular Cancer Study G (2011) Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol 60(4):850–855

    Article  CAS  PubMed  Google Scholar 

  11. Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Bohlke I, Kollmannsberger C, German Testicular Cancer Study G (2008) Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 19(3):448–453

    Article  CAS  PubMed  Google Scholar 

  12. Garraway LA, Verweij J, Ballman KV (2013) Precision oncology: an overview. J Clin Oncol 31(15):1803–1805

    Article  PubMed  Google Scholar 

  13. Squillante CM, Vaughn DJ (2015) Targeted therapies in germ cell tumors. Urol Oncol 33(8):363–369

    Article  PubMed  Google Scholar 

  14. Porcu P, Bhatia S, Sharma M, Einhorn LH (2000) Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 18(6):1181–1186

    Article  CAS  PubMed  Google Scholar 

  15. Kollmannsberger C, Honecker F, Bokemeyer C (2008) Pharmacotherapy of relapsed metastatic testicular cancer. Expert Opin Pharmacother 9(13):2259–2272

    Article  CAS  PubMed  Google Scholar 

  16. Sadeghi S, Quinn D, Tsao-Wei D, Hamid O, Hu J, Schuckman A, Daneshmand S, Groshen S, Raghavan D, Dorff T (2013) Phase II study of gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (pts) with refractory germ cell tumor (rGCT): final results. J Clin Oncol 31(Suppl); abstr 4531

  17. Necchi A, Nicolai N, Mariani L, Lo Vullo S, Giannatempo P, Raggi D, Fare E, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Milani A, Gianni AM, Salvioni R (2014) Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes. Clin Genitourin Cancer 12(1):63–69

    Article  PubMed  Google Scholar 

  18. Zaffaroni N, Fiorentini G, De Giorgi U (2001) Hyperthermia and hypoxia: new developments in anticancer chemotherapy. Eur J Surg Oncol 27(4):340–342

    Article  CAS  PubMed  Google Scholar 

  19. Wessalowski R, Schneider DT, Mils O, Friemann V, Kyrillopoulou O, Schaper J, Matuschek C, Rothe K, Leuschner I, Willers R, Schonberger S, Gobel U, Calaminus G, group Ms (2013) Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study. Lancet Oncol 14(9):843–852

    Article  PubMed  Google Scholar 

  20. Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Flechon A, Margolin K, Lotz JP, Germa-Lluch JR, Powles T, Kollmannsberger C, Beyer J (2011) Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 29(16):2178–2184

    Article  PubMed  Google Scholar 

  21. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Reich LM, Bosl GJ, Motzer RJ (2010) TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 28(10):1706–1713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lorch A, Neubauer A, Hackenthal M, Dieing A, Hartmann JT, Rick O, Bokemeyer C, Beyer J (2010) High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol 21(4):820–825

    Article  CAS  PubMed  Google Scholar 

  23. Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S (2013) Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Rev Mol Med 15:e12

    Article  CAS  PubMed  Google Scholar 

  24. Feldman DR, Bagrodia A, Lee B, Lee W, Al-Ahmadie H, Cha EK, Sfakianos J, Iyer G, Zabor EG, Ostrovnaya I, Eng J, Arcila ME, Chaganti RSK, Schultz N, Reuter VE, Bains M, Sheinfeld J, Carver BS, Bosl GJ, Solit DB (2015) Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT). J Clin Oncol 33(Suppl):abstr 4510

  25. Jacobsen C, Honecker F (2015) Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology 3(1):111–121

    Article  CAS  PubMed  Google Scholar 

  26. Feldman DR, Iyer G, Van Alstine L, Patil S, Al-Ahmadie H, Reuter VE, Bosl GJ, Chaganti RS, Solit DB (2014) Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clin Cancer Res 20(14):3712–3720

    Article  CAS  PubMed  Google Scholar 

  27. Oing C, Bokemeyer C, Russell K, Millis SZ, Bender R, Gatalica Z, Voss A (2015) Molecular profiling of cisplatin-resistant testicular germ cell tumors. Oncol Res Treat 38(Suppl. 5):168–169 (abstr V556)

  28. Juliachs M, Munoz C, Moutinho CA, Vidal A, Condom E, Esteller M, Graupera M, Casanovas O, Germa JR, Villanueva A, Vinals F (2014) The PDGFRbeta–AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res 20(3):658–667

    Article  CAS  PubMed  Google Scholar 

  29. Fukuda S, Shirahama T, Imazono Y, Tsushima T, Ohmori H, Kayajima T, Take S, Nishiyama K, Yonezawa S, Akiba S, Akiyama S, Ohi Y (1999) Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 85(6):1323–1330

    Article  CAS  PubMed  Google Scholar 

  30. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Cutcutache I, Suzuki Y, Tan IB, Ramgopal S, Zhang S, Ramnarayanan K, Gan A, Lee HH, Tay ST, Ooi A, Ong CK, Bolthouse JT, Lane BR, Anema JG, Kahnoski RJ, Tan P, Teh BT, Rozen SG (2015) Exome-wide sequencing shows low mutation rates and identifies novel mutated genes in seminomas. Eur Urol 68(1):77–83

    Article  CAS  PubMed  Google Scholar 

  32. Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, Oechsle K, Steyerberg E, Hartmann JT, Dinjens WN, Oosterhuis JW, Bokemeyer C, Looijenga LH (2009) Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 27(13):2129–2136

    Article  CAS  PubMed  Google Scholar 

  33. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21(1):24–33

    Article  CAS  PubMed  Google Scholar 

  34. Frankhauser CD, Fontecedro AC, Beyer J, Tischler V, Sulser T, Moch H, Bode PK (2015) Frequent expression of PD-L1 in testicular germ cell tumors. J Clin Oncol 33

  35. Gold EJ, Bosl GJ, Itri LM (1984) Phase II trial of 13-cis-retinoic acid in patients with advanced nonseminomatous germ cell tumors. Cancer Treat Rep 68(10):1287–1288

    CAS  PubMed  Google Scholar 

  36. Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ, Dmitrovsky E (1995) All-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer 76(4):680–686

    Article  CAS  PubMed  Google Scholar 

  37. Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED (2006) Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer 106(12):2624–2629

    Article  CAS  PubMed  Google Scholar 

  38. Schmidt BA, Rose A, Steinhoff C, Strohmeyer T, Hartmann M, Ackermann R (2001) Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Cancer Res 61(10):4214–4221

    CAS  PubMed  Google Scholar 

  39. Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R, Slamon D (1991) Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci USA 88(15):6662–6666

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Vaughn DJ, Flaherty K, Lal P, Gallagher M, O’Dwyer P, Wilner K, Chen I, Schwartz G (2009) Treatment of growing teratoma syndrome. N Engl J Med 360(4):423–424

    Article  CAS  PubMed  Google Scholar 

  41. Vaughn DJ, Hwang WT, Lal P, Rosen MA, Gallagher M, O’Dwyer PJ (2015) Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer 121(9):1463–1468

    Article  CAS  PubMed  Google Scholar 

  42. Narayan V, Hwang WT, Lal P, Rosen MA, Gallagher M, O’Dwyer PJ, Vaughn DJ (2016) Cyclin-dependent Kinase 4/6 Inhibition for the treatment of unresectable mature teratoma: long-term follow-up of a phase II study. Clin Genitourin Cancer

  43. Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E, Spinella MJ (2009) High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res 69(24):9360–9366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Roth BJ, Elson P, Sledge GW Jr, Einhorn LH, Trump DL (1993) 5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group. Investig New Drugs 11(2–3):201–202

    Article  CAS  Google Scholar 

  45. Clavel M, Monfardini S, Fossa S, Smyth J, Renard J, Kaye SB (1992) 5-Aza-2′-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Ann Oncol 3(5):399–400

    Article  CAS  PubMed  Google Scholar 

  46. Rick O, Braun T, Siegert W, Beyer J (2006) Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 42(12):1775–1779

    Article  CAS  PubMed  Google Scholar 

  47. Oechsle K, Bokemeyer C, Honecker F (2010) Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. J Cancer Res Clin Oncol 136(1):165–167

    Article  CAS  PubMed  Google Scholar 

  48. Jain A, Brames MJ, Vaughn D, Einhorn L (2011) Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT). J Clin Oncol 29(Suppl):abstr 4579

  49. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L (2015) Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol 26(10):2125–2132

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A (2006) Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 29(1):12–13

    Article  CAS  PubMed  Google Scholar 

  51. Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, Wood L, Fenner M, Glaesener S, Hartmann JT, Chi K, Bokemeyer C, Kollmannsberger C (2011) Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol 22(12):2654–2660

    Article  CAS  PubMed  Google Scholar 

  52. Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ, Motzer RJ (2010) Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Investig New Drugs 28(4):523–528

    Article  CAS  Google Scholar 

  53. Giannatempo P, Nicolai N, Farè E, Raggi D, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Crestani A, Togliardi E, Salvioni R, Gianni AM, Necchi A (2014) Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): first results of the open-label, single-group, phase II PAZOTEST-01 trial. J Clin Oncol 32(Suppl 4):abstr 376

  54. Skoneczna IA, Natorska U, Tacikowska M, Kraszewska E, Kotowicz B, Fuksiewicz M, Rogowski WW, Federowicz I, Poniatowska G, Chaladaj-Kujawska A, Michalski W (2014) Sorafenib monotherapy in patients with inoperable/recurrent germ cell tumors (GCT) refractory to chemotherapy: Phase II study. J Clin Oncol 32(Suppl 4):abstr 367

  55. Steinemann G, Jacobsen C, Gerwing M, Hauschild J, von Amsberg G, Hopfner M, Nitzsche B, Honecker F (2015) Activity of nintedanib in germ cell tumors. Anticancer Drugs

  56. Motzer RJ, Dmitrovsky E, Miller WH Jr, Tong WP, Bajorin DF, Scher HI, Bost GJ (1993) Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer 72(11):3313–3317

    Article  CAS  PubMed  Google Scholar 

  57. Mego M, Svetlovska D, Miskovska V, Obertova J, Palacka P, Rajec J, Sycova-Mila Z, Chovanec M, Rejlekova K, Zuzak P, Ondrus D, Spanik S, Reckova M, Mardiak J (2016) Phase II study of everolimus in refractory testicular germ cell tumors. Urol Oncol 34(3):122

    Article  PubMed  Google Scholar 

  58. Necchi A, Magazzu D, Anichini A, Raggi D, Giannatempo P, Nicolai N, Colecchia M, Paolini B, Coradeshi E, Tassi E, Grazia G, Mortarini R, Calareso G, Togliardi E, Crippa F, Salvioni R, Gianni AM, Valagussa P (2016) An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01). J Clin Oncol 34(Suppl 2S):abstr 480

  59. Rick O, Bokemeyer C, Weinknecht S, Schirren J, Pottek T, Hartmann JT, Braun T, Rachud B, Weissbach L, Hartmann M, Siegert W, Beyer J (2004) Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 22(18):3713–3719

    Article  CAS  PubMed  Google Scholar 

  60. Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP (2005) Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. Urol Oncol 23(6):423–430

    Article  PubMed  Google Scholar 

  61. Masterson TA, Shayegan B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J (2012) Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology 79(1):156–159

    Article  PubMed  Google Scholar 

  62. Daneshmand S, Albers P, Fossa SD, Heidenreich A, Kollmannsberger C, Krege S, Nichols C, Oldenburg J, Wood L (2012) Contemporary management of postchemotherapy testis cancer. Eur Urol 62(5):867–876

    Article  PubMed  Google Scholar 

  63. Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER Jr, Einhorn LH, Roth BJ, Donohue JP (1997) Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 50(6):957–962

    Article  CAS  PubMed  Google Scholar 

  64. Albers P, Ganz A, Hannig E, Miersch WD, Muller SC (2000) Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 164(2):381–384

    Article  CAS  PubMed  Google Scholar 

  65. Heidenreich A, Thuer D, Polyakov S (2008) Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol 53(2):260–272

    Article  PubMed  Google Scholar 

  66. Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP (2005) Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 23(25):6149–6156. doi:10.1200/JCO.2005.11.684

    Article  PubMed  Google Scholar 

  67. Miller JC, Einhorn LH (1990) Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17(1 Suppl 2):36–39

    CAS  PubMed  Google Scholar 

Download references

Authors’ contribution

C Oing was involved in project development, data collection, data analysis and manuscript writing/editing. WH Alsdorf collected data, analyzed data, and wrote and edited the manuscript. G von Amsberg was involved in project development and manuscript writing/editing. K Oechsle was involved in data analysis and manuscript writing/editing. C Bokemeyer developed the project, and wrote and edited the manuscript.

Author information

Author notes

    Authors and Affiliations

    1. Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany

      Christoph Oing, Winfried H. Alsdorf, Gunhild von Amsberg, Karin Oechsle & Carsten Bokemeyer

    Authors
    1. Christoph Oing
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Winfried H. Alsdorf
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Gunhild von Amsberg
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Karin Oechsle
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Carsten Bokemeyer
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Christoph Oing.

    Ethics declarations

    Conflict of interest

    All authors herewith declare that there is no financial or non-financial conflict of interest to bias the development of this manuscript.

    Ethical standard

    As this project is solely a review of the literature, no primary research involving human participants has been conducted, and accordance of the literature included in the manuscript with accepted ethical guidelines has been assumed.

    Additional information

    Christoph Oing and Winfried H. Alsdorf have contributed equally to the manuscript.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Oing, C., Alsdorf, W.H., von Amsberg, G. et al. Platinum-refractory germ cell tumors: an update on current treatment options and developments. World J Urol 35, 1167–1175 (2017). https://doi.org/10.1007/s00345-016-1898-z

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00345-016-1898-z

    Keywords

    Search

    Navigation